Andy Lundin, Author at Hematology Advancements

Blockchain for Personalized Medicine in Hematology: A Game Changer?

Posted by Andy Lundin | Jun 19, 2024 | Technology |

Blockchain tech offers a secure and interoperable platform for managing patient data, enabling personalized treatment plans in hematology.

Posted by Andy Lundin | Jun 14, 2024 | Regulatory Impact |

The FDA regulatory landscape for the approval of hematological drugs involves a structured framework ensuring the efficacy of therapies.

Innovative biologics are supporting beta-thalassemia treatment by enabling long-term remission and improved quality of life via gene therapy.

Posted by Andy Lundin | Jun 14, 2024 | Diagnostic Tools |

Bone marrow biopsy is a crucial diagnostic tool in hematology for identifying and managing blood disorders and cancers.

Posted by Andy Lundin | Jun 14, 2024 | Research Updates |

Clonal hematopoiesis increases the risk of developing hematologic malignancies such as myelodysplastic syndromes and acute myeloid leukemia.